英国GBI对于癌症市场进行了分析表示，对于癌症免疫疗法的研究以每年23.9%的资金增速从2015年的 169亿美元四倍增长到2022年的758亿美元。

　　这份市场报告显示，目前有2,037个通过免疫疗法治疗癌症的产品，占整个癌症治疗法的37%。

　　然而，尽管癌症的免疫疗法已经很成熟，但是早期的产品占了很大一部分比例，近期并没有特别发现能够使治疗手段进一步提升。这就意味着癌症的免疫疗法从实验室理论阶段到临床应用有着一定的困难。

　　这个行业早期产品的水平和近期的水平有着明显的不平衡，在癌症的免疫疗法方面，很多的治疗想法比普通疗法要困难得多。然而这些发现能够使早期疗法更进一步，促成癌症免疫新疗法。

　　The market for cancer immunotherapies is set to swell more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, with a rapid compound annual growth rate of 23.9 percent, predicts business intelligence provider GBI Research.

　　According to the firm's latest market report, there are currently 2,037 products in active development in the cancer immunotherapy pipeline, accounting for 37 percent of the entire oncology pipeline, underscoring the high level of interest in this class of drugs.

　　However, "although the cancer immunotherapy pipeline is clearly strong, a significant proportion is made up of early-stage products, namely those from the Discovery stage to Phase I," noted Yasser Mushtaq, a senior analyst at GBI. "This is indicative of the difficulty associated with progressing cancer immunotherapies from preclinical laboratory studies to clinical application in humans".

　　"The imbalance between early-stage and late-stage product development is more pronounced than typically seen in the industry, and may suggest greater difficulty than normal in developing cancer immunotherapies. However, these findings may also indicate a substantial drive to invest in early-stage cancer immunotherapy development, which could eventually filter through to late-stage product development," he added.

　　The firm's research also indicates that several late-stage pipeline drugs, as well as some already marketed drugs, should achieve blockbuster status by the end of the forecast period, while a number of existing blockbuster therapies - including Celgene's Revlimid (lenalidomide), Bristol-Myers Squibb's Opdivo (nivolumab), MSD's Keytruda (pembrolizumab) and Roche's Gazyva (obinutuzumab) - are expected to experience strong revenue growth.

　　"A number of pipeline products are also forecast to be approved by 2022, some of which are expected to be commercial successes," said Mushtaq, adding that AstraZeneca's durvalumab and tremelimumab, in development as individual therapies and in combination, "will be the most notable products".